Chemotherapy with or without radiation before surgery for esophagogastric junction cancer
Part of Cancer clinical trials.
This trial compares two treatment approaches for a specific type of cancer at the junction of the esophagus and stomach. One approach combines chemotherapy before and after surgery, while the other adds radiation before surgery. The goal is to see which approach helps patients live longer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of adenocarcinoma of the esophagogastric junction (where the esophagus meets the stomach).
- Your cancer must be at a locally advanced stage (cT3-4N+M0) that has not spread to distant organs.
- You must not have had chemotherapy or radiation for this cancer before.
- You must be in generally good health with normal heart, liver, kidney, and other organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
This study tests a new pre-surgery treatment plan that combines chemotherapy with focused, shorter-course radiation for esophagus or stomach-where-it-meets-the-esophagus (GEJ) adenocarcinoma. The goal is to shrink the tumor before surgery and improve treatment outcomes.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.